Adverse Events of Diagnostic Radiopharmaceuticals: A Systematic Review

Nanno Schreuder*, Daniëlle Koopman, Pieter L. Jager, Jos G.W. Kosterink, Eugène van Puijenbroek

*Corresponding author for this work

Research output: Contribution to journalReview articleAcademicpeer-review

11 Citations (Scopus)
2 Downloads (Pure)


Diagnostic radiopharmaceuticals used in nuclear medicine can cause adverse events. Information on these adverse events is available in case reports and databases but may not be readily accessible to healthcare professionals. This systematic review provides an overview of adverse events of diagnostical radiopharmaceuticals and their characteristics. A median frequency for adverse events in diagnostical radiopharmaceuticals of 1.63 (interquartile range: 1.09-2.29) per 100,000 is reported. Most common are skin and subcutaneous tissue disorders, and general disorders and administration site conditions. Many adverse events reported are minor in severity, although 6.7% can be classified as important. In rare cases, adverse events are serious and potentially life-threatening. With the introduction of new radiopharmaceuticals and the increasing use of positron emission tomography-computed tomography, previously unknown adverse events may be detected in daily practice. Future work should cover the experience of the patient with adverse events from diagnostic radiopharmaceuticals.

Original languageEnglish
Pages (from-to)382-410
Number of pages29
JournalSeminars in Nuclear Medicine
Issue number5
Publication statusPublished - Sept 2019


  • n/a OA procedure


Dive into the research topics of 'Adverse Events of Diagnostic Radiopharmaceuticals: A Systematic Review'. Together they form a unique fingerprint.

Cite this